# PCS IX (NCT02685397)

> Management of Castration-Resistant Prostate Cancer with Oligometastases

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02685397
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
- Conditions: Castration-resistant Prostate Cancer Patients with Oligometastases
- Interventions: Leuprolide Acetate; Goserelin Acetate; Triptorelin; Enzalutamide; Stereotactic Body Radiation Therapy
- Enrollment: 102
- Primary outcome: Radiographic Progression-free Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pcs-ix-nct02685397